Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis

Hiroe Ogawa, Hideto Kameda, Hayato Nagasawa, Naoya Sekiguchi, Hirofumi Takei, Kensei Tsuzaka, Koichi Amano, Tsutomu Takeuchi

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

We evaluated the efficacy and safety of low-dose cyclosporine A (CsA) in patients with refractory lupus nephritis. Nine patients with systemic lupus erythematosus who had lupus nephritis resistant to previous treatment with glucocorticoids and immunosuppressants other than CsA were enrolled in a prospective, open-label study. All patients initially received 2.5 mg/kg per day of CsA; the dosage was adjusted to reach a blood trough level of 80-150ng/ml. The urinary protein concentration decreased significantly 2 weeks after the initiation of treatment. After 30 weeks of CsA treatment, the mean urinary protein concentration was more than 50% lower than the baseline value, and urinary casts had decreased significantly. There were no significant changes in the levels of serum creatinine, serum anti-double-stranded DNA antibodies, or CH50 during any part of the study. The dose of glucocorticoids was significantly tapered by approximately 50%, without any disease flare. Hypertension developed in one patient, but was controlled with antihypertensive agents. Our results suggest that low-dose CsA therapy is an effective and less toxic alternative to conventional cyclophosphamide therapy for the management of refractory lupus nephritis.

Original languageEnglish
Pages (from-to)92-97
Number of pages6
JournalModern Rheumatology
Volume17
Issue number2
DOIs
Publication statusPublished - 2007 Apr
Externally publishedYes

Fingerprint

Lupus Nephritis
Cyclosporine
Prospective Studies
Glucocorticoids
Therapeutics
Poisons
Immunosuppressive Agents
Serum
Systemic Lupus Erythematosus
Cyclophosphamide
Antihypertensive Agents
Creatinine
Proteins
Hypertension
Safety
Antibodies
DNA

Keywords

  • Cyclosporine A
  • Immunosuppressivedrugs
  • Lupusnephritis
  • Systemiclupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. / Ogawa, Hiroe; Kameda, Hideto; Nagasawa, Hayato; Sekiguchi, Naoya; Takei, Hirofumi; Tsuzaka, Kensei; Amano, Koichi; Takeuchi, Tsutomu.

In: Modern Rheumatology, Vol. 17, No. 2, 04.2007, p. 92-97.

Research output: Contribution to journalArticle

Ogawa, H, Kameda, H, Nagasawa, H, Sekiguchi, N, Takei, H, Tsuzaka, K, Amano, K & Takeuchi, T 2007, 'Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis', Modern Rheumatology, vol. 17, no. 2, pp. 92-97. https://doi.org/10.1007/s10165-006-0545-8
Ogawa, Hiroe ; Kameda, Hideto ; Nagasawa, Hayato ; Sekiguchi, Naoya ; Takei, Hirofumi ; Tsuzaka, Kensei ; Amano, Koichi ; Takeuchi, Tsutomu. / Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. In: Modern Rheumatology. 2007 ; Vol. 17, No. 2. pp. 92-97.
@article{58a1ff3f84f94397b131f345b6f970de,
title = "Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis",
abstract = "We evaluated the efficacy and safety of low-dose cyclosporine A (CsA) in patients with refractory lupus nephritis. Nine patients with systemic lupus erythematosus who had lupus nephritis resistant to previous treatment with glucocorticoids and immunosuppressants other than CsA were enrolled in a prospective, open-label study. All patients initially received 2.5 mg/kg per day of CsA; the dosage was adjusted to reach a blood trough level of 80-150ng/ml. The urinary protein concentration decreased significantly 2 weeks after the initiation of treatment. After 30 weeks of CsA treatment, the mean urinary protein concentration was more than 50{\%} lower than the baseline value, and urinary casts had decreased significantly. There were no significant changes in the levels of serum creatinine, serum anti-double-stranded DNA antibodies, or CH50 during any part of the study. The dose of glucocorticoids was significantly tapered by approximately 50{\%}, without any disease flare. Hypertension developed in one patient, but was controlled with antihypertensive agents. Our results suggest that low-dose CsA therapy is an effective and less toxic alternative to conventional cyclophosphamide therapy for the management of refractory lupus nephritis.",
keywords = "Cyclosporine A, Immunosuppressivedrugs, Lupusnephritis, Systemiclupus erythematosus",
author = "Hiroe Ogawa and Hideto Kameda and Hayato Nagasawa and Naoya Sekiguchi and Hirofumi Takei and Kensei Tsuzaka and Koichi Amano and Tsutomu Takeuchi",
year = "2007",
month = "4",
doi = "10.1007/s10165-006-0545-8",
language = "English",
volume = "17",
pages = "92--97",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis

AU - Ogawa, Hiroe

AU - Kameda, Hideto

AU - Nagasawa, Hayato

AU - Sekiguchi, Naoya

AU - Takei, Hirofumi

AU - Tsuzaka, Kensei

AU - Amano, Koichi

AU - Takeuchi, Tsutomu

PY - 2007/4

Y1 - 2007/4

N2 - We evaluated the efficacy and safety of low-dose cyclosporine A (CsA) in patients with refractory lupus nephritis. Nine patients with systemic lupus erythematosus who had lupus nephritis resistant to previous treatment with glucocorticoids and immunosuppressants other than CsA were enrolled in a prospective, open-label study. All patients initially received 2.5 mg/kg per day of CsA; the dosage was adjusted to reach a blood trough level of 80-150ng/ml. The urinary protein concentration decreased significantly 2 weeks after the initiation of treatment. After 30 weeks of CsA treatment, the mean urinary protein concentration was more than 50% lower than the baseline value, and urinary casts had decreased significantly. There were no significant changes in the levels of serum creatinine, serum anti-double-stranded DNA antibodies, or CH50 during any part of the study. The dose of glucocorticoids was significantly tapered by approximately 50%, without any disease flare. Hypertension developed in one patient, but was controlled with antihypertensive agents. Our results suggest that low-dose CsA therapy is an effective and less toxic alternative to conventional cyclophosphamide therapy for the management of refractory lupus nephritis.

AB - We evaluated the efficacy and safety of low-dose cyclosporine A (CsA) in patients with refractory lupus nephritis. Nine patients with systemic lupus erythematosus who had lupus nephritis resistant to previous treatment with glucocorticoids and immunosuppressants other than CsA were enrolled in a prospective, open-label study. All patients initially received 2.5 mg/kg per day of CsA; the dosage was adjusted to reach a blood trough level of 80-150ng/ml. The urinary protein concentration decreased significantly 2 weeks after the initiation of treatment. After 30 weeks of CsA treatment, the mean urinary protein concentration was more than 50% lower than the baseline value, and urinary casts had decreased significantly. There were no significant changes in the levels of serum creatinine, serum anti-double-stranded DNA antibodies, or CH50 during any part of the study. The dose of glucocorticoids was significantly tapered by approximately 50%, without any disease flare. Hypertension developed in one patient, but was controlled with antihypertensive agents. Our results suggest that low-dose CsA therapy is an effective and less toxic alternative to conventional cyclophosphamide therapy for the management of refractory lupus nephritis.

KW - Cyclosporine A

KW - Immunosuppressivedrugs

KW - Lupusnephritis

KW - Systemiclupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=34247247141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247247141&partnerID=8YFLogxK

U2 - 10.1007/s10165-006-0545-8

DO - 10.1007/s10165-006-0545-8

M3 - Article

VL - 17

SP - 92

EP - 97

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 2

ER -